Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cardiac ATP-sensitive potassium (KATP) channels are hetero-octameric complexes consisting of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor 2A (SUR2A) subunits (Nichols, 2006, Nature). These channels function as metabolic sensors that link the cellular energetic state to membrane potential by opening in response to a decrease in the intracellular ATP/ADP ratio (Seino & Miki, 2003, Progress in Biophysics and Molecular Biology). In the healthy heart, high ATP levels keep the channels closed, maintaining normal electrical activity. However, during metabolic stress such as myocardial ischemia or hypoxia, the channels open to allow potassium efflux. This action hyperpolarizes the sarcolemma and shortens the action potential duration, which reduces calcium entry and preserves high-energy phosphates. This process provides a critical endogenous cardioprotective mechanism against ischemic injury (Foster & Coetzee, 2016, Physiological Reviews). Pharmacological agents like nicorandil target these channels to mimic this protective effect in patients with stable angina or ischemic heart disease. Conversely, understanding the specific subunit composition is vital for developing cardioselective drugs that avoid off-target effects in the pancreas or vasculature.
Potassium channel openers (KCOs) bind to the regulatory SUR2A subunits to promote channel opening, leading to hyperpolarization and reduced calcium overload during ischemia (Foster & Coetzee, 2016, Physiological Reviews). Conversely, sulfonylurea blockers inhibit the channel by binding to the SUR subunits, preventing potassium efflux and potentially interfering with ischemic preconditioning (Gribble & Reimann, 2003, Diabetologia).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cardiac ATP-sensitive potassium channel (Cardiac KATP channel) (Cardiac KATP channel).